Drug intelligence / Profile preview

ACF-516

Development stage: Preclinical
Lead developer: Avidin

Overview

ACF-516 is an investigational drug candidate currently in the preclinical stage of development for the treatment of cystic fibrosis. Developed by the biotech company Avidin, the specific molecular target and mechanism of action for this compound have not been publicly disclosed in the company's pipeline documentation. It is part of a broader portfolio of therapeutic candidates aimed at addressing significant unmet medical needs in genetic and chronic diseases. As a preclinical asset, it is undergoing early-stage research to evaluate its safety and efficacy profile prior to potential clinical trial initiation.

Targets

BRD7 (Bromodomain-containing protein 7)DCAF16 (DDB1- and CUL4-associated factor 16)

Beyond the preview

Go deeper on ACF-516.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACF-516.

Explore the full profile